Scarica l'app Stockscreener
5.36
6.46%
-0.37
Dopo l'orario di chiusura:
5.46
0.10
+1.87%
Precedente Chiudi:
$5.73
Aprire:
$5.77
Volume 24 ore:
888.07K
Relative Volume:
2.12
Capitalizzazione di mercato:
$427.75M
Reddito:
$16.72M
Utile/perdita netta:
$-77.80M
Rapporto P/E:
-5.0695
EPS:
-1.0573
Flusso di cassa netto:
$-43.78M
1 W Prestazione:
+14.53%
1M Prestazione:
+20.72%
6M Prestazione:
+140.36%
1 anno Prestazione:
+490.96%
Intervallo 1D:
$5.21
$5.91
Intervallo di 1 settimana:
$4.63
$5.91
Portata 52W:
$0.82
$5.91
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
5.36 | 457.27M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance UK
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
EcoR1 Capital LLC Makes New $3.24 Million Investment in Prelude Therapeutics Incorporated $PRLD - MarketBeat
PRLD|Prelude Therapeutics Inc|Price:4.640| - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRLD|Prelude Therapeutics Inc|Price:3.830|Chg%:-0.100 - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Prelude Therapeutics Incorporated Revenue Breakdown – NASDAQ:PRLD - TradingView
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics stock trades around recent lows as clinical pipeline spending weighs on results - Ad-hoc-news.de
Enterprise value to EBITDA forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Enterprise value to revenue forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - Yahoo Finance
Research Analysts Offer Predictions for PRLD Q2 Earnings - MarketBeat
H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Canada
JAK2 inhibitors reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79% - MarketsMojo
Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.com - Investing.com Canada
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2000 Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell Microcap Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 3000E Index - marketscreener.com
MapLight Therapeutics appoints two directors to board - Investing.com UK
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
MapLight Therapeutics Announces Changes to Board of Directors - The Manila Times
Prelude Therapeutics (PRLD) Edges Higher, Approaches Key Resistance at $4.60Overvalued Signals - dars.gov.et
Prelude Therapeutics (PRLD) Edges Lower as Stock Tests Key Support LevelADD Alert - dars.gov.et
PRLD Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Institutional Confidence - TradingKey
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Moomoo
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 21 '26 |
Buy |
4.44 |
2,815,315 |
12,499,999 |
11,808,945 |
0.03%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):